MBX Biosciences

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide&#39;s Phase 3 potential and $2 billion+ market opportunity.

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market

Recent Gains

Pre-Market Outlook

Markets

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

movers image

ALVO

APLD

ARDT

CVGW

ORKA

TBCH

VCEL

Applied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

MBX Biosciences Inc

MICROBIX BIOSYSTEMS INC by Microbix Biosystems Inc.

Microbix Biosystems Inc

Press Releases

MBX Biosciences Announces Additions to Leadership Team

Earnings

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Management

MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences to Participate in June Investor Conferences

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Alumis

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

Maze Therapeutics

Nektar Therapeutics

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Tilray Brands

Tvardi Therapeutics

Zevra Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

JMP Securities

Guggenheim

Jefferies

JP Morgan

Stifel

Comments

MBX Biosciences

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell